glp 1 compounded Novo Nordisk Drops Hims & Hers: Inside the GLP-1 Crisis Why the FDA is cracking
Description
Currently, MASLD is the most common chronic liver disease worldwide, affecting approximately 30% of the global adult population, with prevalence rates reaching 60-70% among patients with T2D 2,3
The peptide pricing landscape changes frequently, so checking current rates before committing to a long-term protocol is essential
Their tendency to cause weight loss is thrusting them into a significant role in the management of obesity
Lacks transparency regarding the pricing
Neuropharmacology , 171, 108091
